Prostate Cancer

Prostate cancer is AR-dependent; castration-resistant progression often involves AR amplification/splice variants, DDR defects, and lineage plasticity. We provide AR/PSA/PSMA biomarker antibodies plus AR antagonists, PARP, and AKT probes for resistance, metabolism, and combinations.

Focus areas: AR signaling & splice variants, PARP in DDR defects, neuroendocrine transdifferentiation, bone metastasis niche

Prostate cancer–related antibodies (curated)

Loading…

Hot topics & directions

  • Next-gen AR antagonist resistance: AR-V7, GR compensation, ligand-independent activation.
  • PARP in HRR defects: BRCA2/ATM germline/somatic synthetic lethality readouts.
  • PI3K/AKT–AR crosstalk: Dual-inhibition windows and metabolic adverse events.
  • Neuroendocrine transdifferentiation: RB1/TP53 co-loss phenotypic switching markers.

Related targets

Androgen axis
AR, KLK3 (PSA), NKX3-1, TMPRSS2
DNA damage repair
BRCA2, ATM, CHEK2, CDK12, PARP1
PI3K / PTEN
PIK3CA/B, PTEN, AKT1/2/3, MTOR
Immunity / checkpoints
CD274 (PD-L1), PDCD1, CTLA4, CD8A

Key signaling pathways

  1. Androgen–AR–chromatin
    AR-driven transcription and resistant clone selection.
  2. PI3K–AKT–mTOR
    PTEN loss amplifies survival; positive feedback with AR.
  3. DDR–cell cycle
    HRR defects & PARP sensitivity; replication-stress coupling.
  4. WNT / EMT (lineage plasticity)
    Research hotspot for adeno-to-neuroendocrine-like transition.

Tool compounds (research use)

Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.

CompoundTargets / pathwaysExperimental notes
EnzalutamideAR (antagonist)CRPC probe; seizure threshold/fatigue monitoring.
AbirateroneCYP17 (androgen synthesis)Adrenal androgen suppression; electrolytes/LFTs.
ApalutamideAR (antagonist)nmCRPC mapping; rash/thyroid function.
OlaparibPARP1/2Synthetic lethality in HRR defects; marrow suppression.
TalazoparibPARP1/2 (potent)Potent DDR probe; higher hematologic toxicity.
IpatasertibAKT1/2/3PTEN-loss PI3K/AKT validation; diarrhea/hyperglycemia.
DarolutamideAR antagonist (structurally distinct)Lower CNS penetration—useful comparator.